Sorry, you need to enable JavaScript to visit this website.

State of the Union: A New Chapter in Colorectal Surgery

 Colon and rectal surgery abstract concept vector illustration

Key Takeaways:

  • For some people with rectal cancer, surgery is now a choice. When exams and imaging show no sign of a tumor after chemotherapy and radiation, close surveillance may be an option. Part of that decision is personal.
     
  • It’s easy to assume that rectal bleeding is from hemorrhoids, especially in a younger adult. With colorectal cancer on the rise in younger people, bleeding deserves an in-person exam at any age
     
  • When it comes to inflammatory bowel disease, it can help to meet a surgeon while there are still medications to try. An early conversation gives patients time to ask what surgery could mean for everyday life and where it fits among their options, before they’re feeling worse and the decision becomes more urgent.

Robert Goldstone, MD, the new chief of colorectal surgery at NewYork-Presbyterian/Columbia, discusses the changing role of surgery in colorectal cancer treatment, the importance of listening to patients, and his vision for more collaborative, accessible care.

Welcome to NewYork-Presbyterian/Columbia! You've spent your career so far in Boston at Mass General Hospital. What drew you here?

It almost feels like a homecoming to me. I was born and raised in New York, and I've always felt like a New Yorker. But it really starts with the history of the institution; Columbia and NewYork-Presbyterian have tremendous reputations, and my wife trained here and raved about it. My brother currently works here [pediatric heart surgeon Andrew Goldstone, MD, PhD] and has had a similarly wonderful experience.

Then there was meeting Dr. Emile Bacha during the interview process. I'd never really met him before, but he's an inspiring figure who truly believes in growing the department and focusing on the colorectal division. I see him as a very promising mentor. I always look at department chairs as mentors whose responsibility is to help the faculty and the divisions beneath them grow.

All those things came together, along with the wonderful opportunity to return home.

I'd love to know what initially drew you to colorectal surgery. Was there something about the field that clicked for you?

When I went to Mass General for my surgical training, I wasn't positive what I wanted to specialize in. I thought general surgery would give me the best possible training and the opportunity to explore different fields. And I gave every field a chance. I considered vascular surgery, thoracic surgery, even plastic surgery.

In the end, what drew me to colorectal surgery was the minimally invasive approach, along with the opportunity to treat both benign and malignant disease, and to do big cases and small cases. It really encompasses everything.

And then there's the blossoming of robotic surgery, which I'm a huge fan of. I try to do everything minimally invasively. I call myself a cosmetic colorectal surgeon.

Was robotics also something you were always interested in? 

My research training actually played a role in that interest. I operated on rodents and pigs in the lab, doing vascular surgery in a plastic surgery lab and even operating under a microscope. I really believe those skills translated to laparoscopic and robotic surgery. You're looking through a different platform, working in a different plane, and manipulating instruments in a similar way.

But it's also the variety. I can have an ambulatory day treating 10 or 15 patients with anorectal conditions, some of whom may be the most grateful patients because you've changed their lives in a pretty quick manner. And then there are emergency operations for colonic perforations or complex cancer surgeries. I feel lucky to have found a field that offers all of that.

Building a Program Around the Patient

Coming in as the new chief, how are you approaching these first few months? What are your priorities?

The first thing is getting to know everyone in the division. I want to meet with people individually and as a team, understand their goals, and figure out how we can align those with the goals of the division. I'm a very friendly, inclusive person, and I want to create a culture where everyone works together and feels part of the same team.

From there, one of my priorities is how we organize our practices and make care more accessible.

There's a tremendous opportunity to expand how we work with advanced practice providers, or APPs [like Nurse Practitioners and Physician Assistants]. My experience has been that pairing APPs with surgeons allows for significant growth in a practice and, importantly, gets patients seen sooner. That's a big limiting factor in healthcare.

What is the APPs role in colorectal care as you see it?

Whether someone has a relatively simple anorectal condition or a new cancer diagnosis, I want the time between referral and evaluation to be as short as possible.

APPs can spend considerable time with patients, answer their questions, help determine whether surgery is necessary, and provide follow-up care. It gives them a more meaningful clinical role, improves access for patients, and helps prevent the entire team from becoming overburdened.

Are there any particular care interests you hope to expand as well?

I'm for sure also interested in developing more integrated centers for specific conditions. Pelvic floor dysfunction is a perfect example. There are so many people, particularly women, who need care for these problems. But a pelvic floor center can't consist of colorectal surgeons alone. You need urogynecology, gastroenterology and motility specialists, pelvic floor physical therapists, and APPs all working together.

We talk about multidisciplinary care all the time in cancer. I think we need to apply that same approach to other disease processes.

Beyond technical skill and clinical outcomes, what separates an exceptional surgical program from a good one?

I think the main thing is patient perception. Clinical outcomes are obviously important, as are innovation and research. But appropriate bedside manner, having patients truly happy with their care and satisfied with their experience, that's the number one thing.

It's why we become physicians.

And in colorectal surgery, we often have these long-term relationships with patients. I've seen some patients for years and years. They continue coming back because they trust me and want help managing their conditions.

The other essential part is teaching. When you train people who carry forward the principles they've learned from you, and then develop their own approaches, you continue to advance the field.

Columbia previously had a colorectal surgery fellowship, and one of my hopes is that we can reestablish that training program. We have excellent surgeons who should be excellent teachers, and both fellows and residents would benefit tremendously.


State of the Union: Advances in Education of Colorectal Diseases


The Changing Landscape of Colorectal Cancer

Looking at the field more broadly, where do you think we've made the greatest progress in recent years?

One area is robotic surgery. We're now performing procedures minimally invasively that traditionally required open operations, including complex rectal cancer cases and parastomal hernia repairs. That can shorten hospital stays and speed recovery.

But the other major area is the evolution of rectal cancer treatment. Year after year, another clinical trial reports results that change how we think about therapy. And it's still evolving.

How has treatment for rectal cancer evolved?

One of the most significant advances is the watch-and-wait approach, or organ preservation. Some patients with rectal cancer undergo total neoadjuvant therapy, meaning chemotherapy and radiation treatment before a planned operation, and achieve a complete clinical response. Instead of proceeding directly to surgery, which could mean living with a colostomy or experiencing low anterior resection syndrome, they may be candidates for close surveillance.

Then there's immunotherapy for tumors with mismatch repair deficiency or microsatellite instability. The responses we've seen in certain trials are incredible, and they could fundamentally change how we manage some of these cancers.

There are still important questions, though. For example, we're studying neoadjuvant immunotherapy in colon cancer, too. Could there be patients who might avoid surgery altogether? We don't know yet. But it's a very exciting area.

It seems that these developments are changing not only how surgeons operate, but whether they operate at all.

A hundred percent. Organ preservation is one of the biggest developments in the field.

The challenge is figuring out whether a complete clinical response truly represents a complete pathologic response. We can examine the patient, perform endoscopy, obtain imaging, and see no evidence of tumor, but that doesn't necessarily mean every cancer cell is gone.

There's also ongoing research into salvage surgery for patients who experience regrowth after watch-and-wait management. We need to understand who can safely undergo surveillance and what happens if treatment is ultimately needed.

And then there are patients with significant medical comorbidities whose risks from surgery may outweigh the benefits. If someone has a microsatellite-unstable tumor that responds to immunotherapy, could we eventually consider surveillance for certain colon cancers as well?

With all this development, is surgery still the go-to method?

Right now, surgery remains the standard approach for most localized colon cancers. But the question is whether we might someday cure selected patients of their cancer without putting them through an operation they may not tolerate.

You’ve mentioned the many factors involved in deciding between treatment strategies for rectal cancer. How do you approach those decisions?

It all starts when you meet the patient, and it really has to be multidisciplinary.

We're working together with medical oncology and radiation oncology to determine the best treatment approach. Some patients benefit from upfront surgery because of their tumor characteristics. Others benefit from neoadjuvant therapy.

We have studies that help guide those decisions, including PRODIGE 23 and OPRA. But what's essential is following the patient throughout the process.

I want to examine the patient and see the tumor initially, whether through a digital rectal exam or flexible sigmoidoscopy, and then reassess after treatment. We're combining those examinations with repeat imaging, including MRI, and tumor markers.

If someone achieves a complete clinical response, the next decision is very individualized.

Some patients don't want to live with the possibility of local regrowth or the commitment of frequent surveillance examinations. Others want to preserve their rectum and avoid surgery if they can safely do so.

Neither decision should be based on one physician's opinion. It needs to be a team approach, with the patient involved in understanding the options.

Is that multidisciplinary structure something you're hoping to develop further at Columbia?

Yes, absolutely. I've already been speaking with colleagues in medical oncology and radiation oncology, and there's a strong foundation here.

There are tumor boards and a lot of expertise, but different physicians may have different opinions about treatment pathways. The opportunity is to come together and establish a coordinated approach while recognizing that each patient's treatment is individual.

That's what I want us to continue building.

Earlier Diagnosis and the Questions We Still Can't Answer

We can't talk about colorectal cancer today without discussing the rise in younger patients. What concerns you most about what you're seeing?

One of the biggest concerns is that younger patients are often presenting with later-stage disease. And if we could identify their cancers earlier, their prognosis could be significantly better.

I've treated teenagers with colorectal cancer, including patients without any known genetic abnormalities. Those are very difficult cases.

We understand certain hereditary syndromes, like Lynch syndrome and familial adenomatous polyposis, but the vast majority of younger patients we're seeing don't have those conditions.

Wow. Are there any leads to why this may be happening in younger and younger people?

So what else is happening, we don’t really know yet. Are there environmental exposures? Is it something related to the microbiome? These are questions researchers are continuing to investigate.

In the meantime, we need to identify and treat these patients appropriately. If I see a 35-year-old with rectal bleeding or a change in bowel function and there's no obvious anorectal source, I generally recommend a colonoscopy.

Do you think we'll eventually see the recommended screening age lowered again?

I do, but I think it could take a long time.

There are always questions about risk, population-level benefit, and cost-effectiveness. It took years for the recommendation to move to age 45. Will we eventually move to 40? Or will we rely more on other screening methods?

Stool-based testing is valuable, especially if it's something a person is willing to do who otherwise wouldn't be screened. But we have to recognize the differences between these tests.

And colonoscopy itself is important. Cologuard, or multitarget stool DNA testing, is good at detecting existing cancers but not precancerous polyps. Colonoscopy gives us the opportunity to identify and remove polyps before they develop into cancer.

So the question becomes, could we have prevented a cancer by performing a colonoscopy earlier?

Are there other common misconceptions that concern you?

Hemorrhoids. Everyone thinks they have hemorrhoids! Even their doctors think they have hemorrhoids.

People are referred for hemorrhoids all the time, and they assume that anything happening around their anus must be hemorrhoids. But that's not always the case. A patient comes in with rectal bleeding and assumes that's the explanation. Sometimes, after an appropriate examination, I diagnose anal cancer or rectal cancer.

That's especially concerning with the increasing incidence of colorectal cancer in younger people. We can't assume that bleeding is benign simply because someone is young.

And there's another issue, which is that we're seeing more virtual visits. And obviously you can't perform an anorectal examination virtually. These conditions require an appropriate physical examination, and patients need to feel comfortable seeking one.



Beyond Cancer: Quality of Life and Everyday Care

What's the most common question patients ask you?

Probably the most common is, "I have so much pain in my butt. What can I do to fix this?"

And of course, it depends on what's causing the problem. But a lot of what I talk to patients about involves their everyday habits, and yes, how much time they're spending on the toilet is part of that.

The use of the iPhone, smart devices, has really evolved into sitting longer on the toilet, unfortunately. I used to talk to patients about reading newspapers and magazines on the toilet. Now it's all about their smartphones. People are sitting there much longer, and that can 100% lead to rectal issues. 

Are you worried that the kids growing up with these devices will develop worse issues?

It’s a concern; starting earlier is the predecessor to things worsening sooner. I like to joke that the difference between a magazine and a smartphone is that you can set an alarm on your phone. Set it, time yourself on the toilet. If I didn't joke around a little, I couldn't do this job. But the timing part isn’t the joke!

Columbia has a long history of treating patients with extremely complex colorectal conditions, including revisions. What does it take to care for someone who's maybe been told there’s nothing else to be done elsewhere?

It takes patience, knowledge, and experience. But more than anything, I think it’s knowing the patient wants to be heard.

When someone has gone from physician to physician or has experienced a poor outcome, the first thing is listening and demonstrating that you understand what they've been through. Then we can begin figuring out how to help them.

Experience matters because you need to understand which options may still be available. But you also have to understand the patient's goals. They may have one treatment in mind without having considered alternatives that could provide a better quality of life. That's really what we're trying to achieve.

With the tremendous expansion of medical therapies for inflammatory bowel disease (IBD), has the relationship between gastroenterologists and colorectal surgeons changed?

It remains a true multidisciplinary relationship, and I think that's essential.

At Mass General, we had regular meetings to review complex IBD cases, bringing together different specialists to determine the best treatment pathway. For these patients, surgery should be a combined decision. It's not simply that someone sees a surgeon and is told they need an operation.

We need to consider which medical therapies they've tried, what options remain, and whether surgery might make sense before moving to another medication. One of the most important things is introducing the possibility of surgery early enough that patients can make an informed decision.

When should patients meet a surgeon?

I don't think patients should first meet a surgeon after they've exhausted every medication, their nutrition has deteriorated, and they're in a much more difficult position. That doesn't mean they necessarily need surgery. It means they should understand what surgery involves and where it fits among their options.

That's where the relationship between gastroenterology and colorectal surgery becomes so important.


Good Girl Greta: What the Body Was Saying All Along


Is there an area of benign colorectal disease where you think we still have significant room for improvement?

Anal fistulas are one. They can be among the most difficult benign anorectal conditions to treat.

If a fistulotomy can safely be performed, it's a very effective operation, with success rates often around 90 to 95 percent. But not every fistula is suitable for that approach.

For more complex fistulas, we have other procedures, including endorectal advancement flaps and LIFT procedures, but their success rates aren't always as promising. There was considerable excitement about treatments involving mesenchymal stem cells, for example, but the results of multicenter trials have been disappointing.

It's an area where patients can face a long course of treatment, and we still need better options.

What about diverticulitis?

Diverticular disease is another important area, particularly because it's so common.

We no longer necessarily recommend surgery simply because someone has experienced a certain number of episodes of uncomplicated diverticulitis. The decision is much more individualized, taking into account the effect on the patient's quality of life.

And there's been an interesting change in medical management. Randomized trials have shown that selected patients with uncomplicated diverticulitis can recover without antibiotics. Yet in the United States, antibiotics are still prescribed very frequently.

I discuss this with my patients, and many are shocked to hear it. They simply haven't been told that antibiotics may not be necessary for every episode.

That’s a good example of the gaps that can exist between research and practice. Why is it so difficult to filter down these findings in a wider way?

I think that's one of the biggest challenges in medicine: adopting the principles established by our research. In cancer care, you sometimes see new evidence incorporated more quickly, particularly at major academic centers, because a treatment may offer a substantial improvement in prognosis.

But implementing those changes across the entire healthcare system is another matter. And for benign conditions, it can be even harder to get providers to follow the most current evidence and recommendations.

We need to do a better job of translating what we've learned into how patients are actually treated.

Looking Ahead

If we were to sit down again five years from now, what would you most hope had changed in colorectal surgery?

The continued expansion of organ-preserving treatment for colorectal cancer. That's number one for me.

I hope we'll see further advances in immunotherapy and in our ability to determine which patients have achieved a complete response to treatment. We also need to improve how we monitor those patients and distinguish a complete clinical response from a complete pathologic response.

There's tremendous potential there. And I think the more we learn, the more opportunities we'll have to individualize treatment and potentially spare patients major surgery.

Finally, after all the training, research, and time spent in the operating room, what's the most rewarding part of your job?

Honestly, it's seeing patients postoperatively. We sometimes talk about postoperative visits as something we have to fit into an already busy schedule. But in reality, they're one of my favorite parts of the job.

Seeing patients so happy and thankful because their quality of life has changed, even for benign issues, is incredibly rewarding. Of course, cancer patients are often extremely grateful to have had their cancer removed. But sometimes it's the smaller procedures that make an enormous difference.

Someone comes in embarrassed because they're bleeding through their underwear from hemorrhoids. Or a patient with rectal prolapse can't even leave the house because they're incontinent. Then you treat them, and they come back and tell you they're living their life again. They're able to go out, return to their regular activities, do the things they couldn't do before.

Those are the most gratifying moments in this job. It's really about seeing the improvement in people’s lives.

Related:


Subscribe to Healthpoints and never miss an update.